REVO-UWD-03

N/A

Report date: 2026/05/21 20:00:22

Base Information

Drug NameREVO-UWD-03

Drug Alias NameUniversal GPC3-CAR-T cellsREVO-UWD-03

ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapyCell and gene therapy > Cell therapy > Donor > Allogeneic

Mechanisms of ActionT lymphocyte replacementsGlypican-3 modulators

TargetsGlypican-3

Therapy Area/IndicationsCarcinoma, Non-Small-Cell LungCarcinoma, Hepatocellular

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryMainland China

CombinationsNo

Global Highest StatusPending (Phase 1 Clinical)

Highest Status in ChinaPending

Originator CompaniesWondercel Therapeutics Co Ltd

China Registration ClassN/A

Develop Information

Active CompaniesN/A

Inactive CompaniesWondercel Therapeutics Co Ltd

Active IndicationsN/A

Inactive IndicationsCarcinoma, Non-Small-Cell LungCarcinoma, Hepatocellular

Other Information

ATC CodeN/A